Vaccinex, Inc.

Overview

Overview

Vaccinex, Inc. is a clinical-stage biotechnology company headquartered in Rochester, New York, dedicated to developing novel therapies for patients with cancer and neurodegenerative diseases. The company leverages its proprietary Signal leopard (S-L) antibody engineering platform to discover and develop monoclonal antibodies that target key signaling pathways involved in disease progression. [@clinicaltrialsgov]

Company Overview

| Attribute | Details | [@sciencedirect]
|-----------|---------|
| Headquarters | Rochester, New York, USA |
| Founded | 1997 |
| Ticker | VCNX (NASDAQ) |
| Focus Areas | Neurodegenerative diseases, Cancer |
| Platform | ActivMAb® antibody discovery |

Funding

• IPO: 2019 (NASDAQ: VCNX)

Pipeline and Programs

Pepinemab (VX-15/2503)

Pepinemab is a humanized monoclonal IgG4 antibody that binds and blocks SEMA4D signaling. It is currently under investigation for both neurological and oncology applications. SEMA4D is an extracellular signaling molecule that regulates immune and inflammatory cell migration and activation, playing roles in tumor immune evasion and neuroinflammation.

Neurology Programs

SIGNAL — Huntington's Disease Trial (Completed 2020/2021):
The company's initial neurodegenerative focus was Huntington's disease, where the Phase 2 SIGNAL trial was completed. This trial evaluated the safety and efficacy of pepinemab in patients with early to mid-stage Huntington's disease.

SIGNAL-AD — Alzheimer's Disease Trial:
Vaccinex has advanced pepinemab into a Phase 1b/2 trial for Alzheimer's disease (SIGNAL-AD), investigating the role of SEMA4D inhibition in reducing neuroinflammation and preserving cognitive function. Positive topline data from this trial indicated cognitive benefit.

December 2025 Development:
The company announced a "$60 million Agreement to Finance a Phase 2b clinical trial of pepinemab to treat Alzheimer's Disease," representing a significant investment in advancing this program toward later-stage clinical development.

Historical PD Program

The company previously investigated VX-15 in Parkinson's disease, focusing on its potential to modify disease progression through modulation of neuroinflammation. While the PD program appears to have been deprioritized in favor of AD and HD, the SEMA4D mechanism remains relevant to PD pathology as documented in the scientific literature.

Semaphorin 4D Biology in Neurodegeneration

Semaphorin 4D (SEMA4D) is a transmembrane signaling molecule that plays complex roles in neuroinflammation and neural repair. The protein is expressed by activated microglia and infiltrating immune cells in the central nervous system[@moreira2023](https://pubmed.ncbi.nlm.nih.gov/37654321/).

Pro-inflammatory Effects:

• SEMA4D binding to Plexin-B1 receptors on neurons promotes inflammatory cytokine release
• SEMA4D inhibits oligodendrocyte differentiation and myelination
• Elevated SEMA4D levels detected in PD and AD patient brains

• Blocking SEMA4D reduces microglial activation and pro-inflammatory cytokine production
• SEMA4D neutralization promotes neural progenitor cell migration and repair
• Combination with immunomodulatory approaches may enhance efficacy

Clinical Development of Pepinemab

SIGNAL Trial — Huntington's Disease

The SIGNAL trial was Vaccinex's initial Phase 2 clinical program in neurodegeneration, evaluating pepinemab in patients with early to mid-stage Huntington's disease. This trial was designed to assess the safety, tolerability, and efficacy of the anti-SEMA4D antibody in modifying disease progression.

Trial Design:

• Enrollment: Patients with early-stage Huntington's disease
• Primary Endpoints: Safety, tolerability, and cognitive function measures
• Secondary Endpoints: Motor function, behavioral outcomes, biomarker modulation

SIGNAL-AD — Alzheimer's Disease Trial

The SIGNAL-AD trial represents Vaccinex's current focus in neurodegeneration. This Phase 1b/2 trial investigates pepinemab in patients with early to moderate Alzheimer's disease.

Trial Rationale:

• Neuroinflammation is a key driver of AD progression
• SEMA4D-mediated signaling contributes to microglial activation and inflammatory cytokine release
• Blocking SEMA4D may preserve neuronal function and slow cognitive decline

• Positive topline data indicating cognitive benefit
• Generally well-tolerated safety profile
• Evidence of target engagement and biomarker modulation

Broader Neurodegeneration Applications

Given the role of neuroinflammation across neurodegenerative conditions, pepinemab has potential applications beyond HD and AD:

| Indication | Rationale | Development Status |
|------------|-----------|---------------------|
| Multiple System Atrophy | SEMA4D in oligodendrocyte dysfunction | Research stage |
| Parkinson's Disease | Microglial activation, neuroinflammation | Previously investigated, not currently active |
| Amyotrophic Lateral Sclerosis | Neuroinflammation in motor neurons | Preclinical exploration |

Clinical Data Summary

Safety Profile:

• Pepinemab has demonstrated a generally favorable safety profile across multiple clinical trials
• Most common adverse events related to infusion reactions
• No significant immunogenicity concerns
• No dose-limiting toxicities identified

• Cognitive benefit observed in SIGNAL-AD Alzheimer's disease trial
• Biomarker evidence of reduced neuroinflammation
• Potential disease-modifying mechanism based on immunomodulation

Preclinical Programs

Vaccinex has additional preclinical programs targeting other mechanisms involved in neurodegenerative processes, including:

• Additional antibodies targeting immune checkpoint pathways
• Novel approaches to modulate neuroinflammation
• Combination approaches with existing immunomodulatory agents

Cancer Programs

Vaccinex has also developed antibodies targeting SEMA4D for oncology applications, recognizing the role of SEMA4D in tumor immunity and metastasis.

KEYNOTE-B84 — Phase 2 trial in recurrent/metastatic head and neck squamous cell carcinoma (combined with pembrolizumab)

Phase 1b/2 — Non-small cell lung cancer (combined with avelumab)

The company's immuno-oncology strategy leverages SEMA4D's role in regulating immune cell trafficking and activation within the tumor microenvironment.

Discovery Platform: ActivMAb®

Vaccinex leveraged its proprietary ActivMAb® discovery platform for antibody generation against complex multipass membrane proteins (GPCRs, ion channels). The platform enables rapid selection of high-affinity human monoclonal antibodies.

Strategic Partnerships

Vaccinex has collaborated with academic institutions and pharmaceutical companies to advance its pipeline, including partnerships focused on understanding the role of Sema4D in neurodegeneration.

Competitive Landscape

Vaccinex operates in the neuroinflammation therapeutic space with several competitors targeting different mechanisms:

| Company | Drug | Target | Mechanism | Status |
|---------|------|--------|-----------|--------|
| Biogen | BIIB122 | LRRK2 | Kinase inhibitor | Phase 2 |
| Roche | Gantenerumab | Amyloid-β | Monoclonal antibody | Phase 3 |
| Prothelia | Protollin | TLR2/4 | Immunomodulator | Phase 1 |
| AC Immune | Semorinemab | Tau | Anti-tau antibody | Phase 2 |
| Vaccinex | Pepinemab | SEMA4D | Immunomodulation | Phase 2 |

Vaccinex Differentiation:

• Unique SEMA4D targeting mechanism distinct from amyloid and tau approaches
• Dual application in neurodegeneration and oncology
• Proprietary ActivMAb platform for antibody discovery
• Strong scientific foundation in semaphorin biology

• Larger companies have more resources for clinical development
• Competing mechanisms (anti-amyloid, anti-tau) have more clinical validation
• Need to demonstrate clear efficacy advantage in later-stage trials
• Funding constraints typical for small biotech companies

Financial Overview

Vaccinex is publicly traded on NASDAQ under the ticker symbol VCNX. The company has focused its resources on advancing its clinical and preclinical programs in both neurodegeneration and oncology.

Key Financial Metrics:

• Market Cap: Approximately $50-100 million (as of early 2026)
• Cash Position: Supported by December 2025 $60 million financing agreement
• Revenue: Minimal, primarily from research collaborations

Relevance to Neurodegenerative Disease Research

Vaccinex's approach to targeting neuroinflammation through SEMA4D represents an alternative mechanism to more traditional amyloid and [tau](/proteins/tau)-targeted approaches in Alzheimer's disease. The company's focus on modulating immune cell signaling provides insights into the role of neuroinflammation in Parkinson's disease progression.

SEMA4D as a Therapeutic Target

The rationale for targeting SEMA4D in neurodegenerative diseases stems from its central role in coordinating neuroinflammatory responses:

Microglial Activation:
SEMA4D is a key regulator of microglial activation states. In the healthy brain, microglia exist in a surveillance mode, continuously scanning their environment. In neurodegenerative conditions, SEMA4D signaling promotes transition to an activated, pro-inflammatory phenotype characterized by increased cytokine production, phagocytic activity, and potential neurotoxicity. Blocking SEMA4D can shift microglia toward a more protective, anti-inflammatory state.

Neuroinflammation Cascade:
SEMA4D orchestrates a cascade of inflammatory events in the CNS. When SEMA4D binds to its receptors (Plexin-B1 on neurons and oligodendrocytes, CD72 on immune cells), it triggers downstream signaling that amplifies production of pro-inflammatory cytokines including IL-1β, TNF-α, and IL-6. This creates a self-perpetuating cycle of neuroinflammation that drives disease progression.

Oligodendrocyte Function:
SEMA4D inhibits oligodendrocyte precursor cell (OPC) differentiation and myelination. In conditions like multiple system atrophy (MSA) and potentially AD, this contributes to white matter damage and neuronal connectivity deficits. SEMA4D blockade may support remyelination and white matter integrity.

Advantages of Immunomodulation Approach

Targeting SEMA4D offers several potential advantages over other therapeutic approaches:

Comparison with Other Immunomodulatory Approaches

| Approach | Target | Company | Status |
|----------|--------|---------|--------|
| Anti-SEMA4D | SEMA4D | Vaccinex | Phase 2 |
| Anti-TREM2 | TREM2 | Various | Preclinical |
| Anti-CD47 | CD47 | Checkpoint inhibitors | Oncology |
| CSF1R inhibitors | CSF1R | Various | Phase 1/2 |
| NLRP3 inhibitors | NLRP3 inflammasome | Various | Preclinical |

Each approach targets different aspects of neuroinflammation. SEMA4D inhibition represents a distinct mechanism affecting both innate immune cell trafficking and activation.

Market Opportunity

Alzheimer's Disease Market

The global Alzheimer's disease therapeutic market represents one of the largest opportunities in pharmaceutical development:

• Prevalence: Over 55 million people worldwide with Alzheimer's and related dementias
• Market Size: Approximately $30 billion annually, growing at 8-10% CAGR
• Unmet Need: No disease-modifying therapies available; current treatments provide only symptomatic benefit

Parkinson's Disease Market

• Prevalence: Over 10 million people worldwide
• Market Size: Approximately $5-6 billion annually
• Unmet Need: No disease-modifying therapies approved; current treatments address symptoms only

Huntington's Disease Market

• Prevalence: Approximately 200,000-300,000 people worldwide
• Market Size: Relatively small, but premium pricing potential
• Unmet Need: No approved disease-modifying therapies

Manufacturing and Operations

Antibody Manufacturing

Vaccinex operates through a combination of internal capabilities and contract manufacturing organizations (CMOs):

Current Manufacturing:

• Produces pepinemab through GMP-qualified CMOs
• Has established scalable manufacturing processes for clinical supply
• Maintains sufficient inventory for ongoing clinical trials

• Phase 2b trial will require significantly increased manufacturing capacity
• Company likely to expand CMO partnerships or invest in internal manufacturing
• Tech transfer and process validation will be critical for late-stage development

Operational Structure

Headquarters: Rochester, New York, USA Employees: Approximately 50-100 employees Operations: Focus on clinical development, with external manufacturing and administrative support

The company leverages a virtual, asset-light operational model typical of clinical-stage biotechnology companies, minimizing fixed costs while maintaining core competencies in research and clinical development.

Future Directions

Near-term Priorities (2026-2027)

• Phase 2b Alzheimer's Trial: Advance pepinemab into Phase 2b trial with $60 million financing
• SIGNAL-AD Continuation: Complete SIGNAL-AD trial and analyze full dataset
• KEYNOTE-B84 Oncology Trial: Continue Phase 2 head and neck cancer trial
• Regulatory Strategy: Engage with FDA and EMA on path forward for AD indication

Research Priorities

• Understanding SEMA4D Biology: Further elucidating SEMA4D's role in neurodegeneration
• Combination Approaches: Testing pepinemab with other immunomodulatory agents
• Patient Selection: Identifying biomarker-defined patient subgroups who may benefit most
• Biomarker Development: Developing SEMA4D and inflammatory biomarkers for patient stratification

Long-term Vision

Vaccinex aims to establish SEMA4D inhibition as a validated therapeutic approach for neurodegenerative diseases. The company's dual-focus strategy on both neurology and oncology provides operational flexibility and multiple shots on goal. With the December 2025 financing in place, the company is positioned to execute on its Phase 2b Alzheimer's trial and potentially expand into additional indications.

See Also

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Neuroinflammation](/mechanisms/neuroinflammation)
• [Semaphorin Signaling](/mechanisms/semaphorin-signaling-neurodegeneration)

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
• [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

References